Despite the fact that migraine is a common disorder, the pathogenesis is still not fully elucidated. Studying transcriptomic and biochemical changes during induced and spontaneous migraine-attacks will enhance our understanding and may point to new targets for drug development.
Migraine is a common neurological disorder affecting approx. 16 % of the European population. Despite the fact that migraine is a common disorder, the pathogenesis is still not sufficiently known. Studying transcriptomic and biochemical changes during spontaneous migraine-attacks will greatly enhance our understanding of migraine mechanisms and may point to new targets for drug development. Two blood samples (one for RNA analysis and one for biochemical analysis) are taken on minimum 15 patient with migraine with aura and 15 patients with migraine without aura when they experience a spontaneous migraine attack. A second sample is taken 2 hours after treatment with subcutaneous sumatriptan. Another two blood samples are taken when the patient has been migraine free for at least 5 days and had no other headache for at least 24 hours. A fourth set of blood samples are collected after a cold pressor test.
Study Type
OBSERVATIONAL
Enrollment
30
There is no intervention, but we will take blood samples during a spontaneous migraine attack
Emma Katrine Hansen
Copenhagen, Glostrup, Denmark
Transcriptomic changes
The investigators will measure transcriptomic changes using Next Generation Sequencing during a migraine attack
Time frame: 2 year
Changes in CGRP levels during a migraine attack (CGRP1-37, CGRP1-17, CGRP18-37, CGRP1-26, CGRP27-37)
The investigators will use advanced mass spectrometry to measure CGRP levels
Time frame: 2 year
Changes in PACAP levels during a migraine attack (PACAP-27, PACAP-38 )
The investigators will use advanced mass spectrometry to measure PACAP levels
Time frame: 2 years
Changes in VIP, glutamate, serotonin, PGE-2, nitric oxide metabolites, cAMP, and cGMP
The investigators will use advanced mass spectrometry to measure VIP, glutamate, serotonin, PGE-2, nitric oxide metabolites, cAMP, and cGMP during a migraine attack
Time frame: 2 years
Changes in Metabolomics
The investigators will use advanced mass spectrometry (LC-MS) to measure metabolomics in the 4 blood samples
Time frame: 3 years
Changes in Proteomics
The investigators will use advanced mass spectrometry to measure proteomics in the 4 blood samples
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.